Version June 2024
| Larotrectinib[1] | Entrectinib[2] | |
| Design | Multiple studies | Multiple studies |
| Number | 159 | 54 |
| Age group, n (%) | ||
| <18 years | 52 (33%) | 0¶ |
| ≥18 years | 107 (67%) | 54 (100%) |
| Age, median | 43 years | 57 years |
| Tumor types | ||
| Sarcoma other than fibrosarcoma or GIST | 36 (23%) | 13 (24%) |
| Salivary | 21 (13%) | 7 (13%) |
| Infantile fibrosarcoma | 29 (18%) | 0 (0%) |
| Thyroid | 26 (16%) | 5 (9%) |
| Lung cancer | 12 (8%) | 10 (19%) |
| Melanoma | 7 (4%) | 0 (0%) |
| Colon | 8 (5%) | 4 (7%) |
| Cholangiocarcinoma | 2 (1%) | 1 (2%) |
| Pancreatic | 2 (1%) | 3 (6%) |
| Breast | 5 (3%) | 6 (11%) |
| Neuroendocrine | 0 (0%) | 3 (6%) |
| Gynecologic | 0 (0%) | 2 (4%) |
| Gastrointestinal stromal tumor | 3 (5%) | 0 (0%) |
| Appendix | 1 (<1%) | 0 (0%) |
| Overall response rate, % (95% CI) | 79% (72 to 85) | 57% (43 to 71) |
| Complete response | 16% | 7% |
| Partial response | 63% | 50% |
| Intracranial response rate | NRΔ | 71% (5 of 7) |
| Duration of response, months (95% CI) | 35.2 (22.8 to non-estimable) | 10.4 (7.1 to NE) |
| Median follow-up time, months | 12.9 | NR |
| Duration of response estimates | ||
| 9 months | – | 59% |
| 12 months | 80% | – |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
